Linas Padegimas
About Linas Padegimas
Linas Padegimas is a Senior Director of Product Development at Abeona Therapeutics, Inc., with a strong academic background in Chemistry and Biochemistry. He has held various scientific positions in the biotechnology sector, including roles at Athersys Inc. and Copernicus Therapeutics Inc.
Work at Abeona Therapeutics
Linas Padegimas has been serving as the Senior Director of Product Development at Abeona Therapeutics, Inc. since 2015. In this role, he is responsible for overseeing the development of innovative therapies aimed at treating rare diseases. His extensive background in biochemistry and molecular biology supports his leadership in product development, ensuring that the company advances its therapeutic candidates through various stages of clinical development.
Education and Expertise
Linas Padegimas holds a Master's degree in Chemistry with a major emphasis in Biochemistry from Vilnius University, where he studied from 1984 to 1989. He further advanced his education by obtaining a PhD in Chemistry with a focus on Molecular Biology from the Engelhardt Institute of Molecular Biology, Academy of Sciences of Russia, between 1989 and 1993. His academic background equips him with a strong foundation in both biochemistry and molecular biology, essential for his roles in product development and research.
Background
Linas Padegimas has a diverse professional background in the field of molecular biology and product development. He began his career as an Assistant Scientist at Vilnius University from 1993 to 1995. He then transitioned to a Postdoctoral Researcher position at Mississippi State University, where he worked from 1995 to 2001. Following this, he served as an Associate Scientist at Athersys Inc. from 2001 to 2005 and later as the Director of Molecular Biology at Copernicus Therapeutics Inc. from 2012 to 2015, both in the Cleveland/Akron, Ohio area.
Professional Experience
Throughout his career, Linas Padegimas has accumulated significant experience in various roles within the biotechnology sector. His tenure at Athersys Inc. as an Associate Scientist involved contributions to research and development projects. At Copernicus Therapeutics Inc., he held the position of Director of Molecular Biology, where he led initiatives in molecular biology research. His roles have consistently focused on advancing therapeutic solutions, reflecting his expertise in product development and scientific research.